Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 103 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RR Clear all
Completed Phase 4 Interventional Results available

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

NCT00176592
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Betaseron, Copaxone
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 19, 2026, 5:18 PM EDT
Completed Not applicable Interventional

Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients

NCT03356184
View directory record Official record
Conditions
Vital Sign Monitoring
Interventions
The Rhea Vital Sign Vigilance Device Group, The Earlysense System Device Group
Device
Lead sponsor
Darma Inc.
Industry
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 19, 2026, 5:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

NCT07225413
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules
Dietary Supplement
Lead sponsor
Jacksonville State University
Other
Eligibility
18 Weeks to 40 Weeks
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Jacksonville, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 19, 2026, 5:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of RR-HNK in OCD

NCT06575075
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
RR-HNK/Hydroxynorketamine, Placebo
Drug
Lead sponsor
Carolyn Rodriguez
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 19, 2026, 5:18 PM EDT
Recruiting Not applicable Interventional

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

NCT07558265
View directory record Official record
Conditions
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 5:18 PM EDT
Terminated No phase listed Observational

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

NCT00919217
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 19, 2026, 5:18 PM EDT
Terminated Phase 1 Interventional

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01985477
View directory record Official record
Conditions
Myeloma
Interventions
Lenalidomide, Dexamethasone, All-Trans Retinoic Acid (ATRA)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 19, 2026, 5:18 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position

NCT02548624
View directory record Official record
Conditions
Patient Positioning, Monitoring, Physiologic, Pressure Ulcer
Interventions
Zephyr BioPatch
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 19, 2026, 5:18 PM EDT
Terminated Phase 1 Interventional

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

NCT05828589
View directory record Official record
Conditions
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions
BGB-21447
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Iowa City, Iowa • Waukee, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 19, 2026, 5:18 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by PIVA

NCT04324593
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Peripheral intravenous analysis (PIVA) algorithm
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 19, 2026, 5:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development of a Resiliency Training Program for Parents of Children With Autism Spectrum Disorder

NCT02995408
View directory record Official record
Conditions
Stress
Interventions
Relaxation Response Resiliency Program for Parents of Children with ASD
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 19, 2026, 5:18 PM EDT
Terminated Phase 1 Interventional

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

NCT04401020
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
SAR442257
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Duarte, California • Miami, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 5:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit

NCT02905656
View directory record Official record
Conditions
Smoking Cessation
Interventions
Brief Advice, Motivational Interviewing, Rate Reduction, Pharmacological, MI+RR
Behavioral · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 19, 2026, 5:18 PM EDT
Active, not recruiting Not applicable Interventional

Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease

NCT05737602
View directory record Official record
Conditions
Von Hippel-Lindau Disease, Genetic Disorder
Interventions
3RP-VHL
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 19, 2026, 5:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients

NCT04954157
View directory record Official record
Conditions
Hypoxia, SARS-CoV-2 Acute Respiratory Disease, Carotid Bodies
Interventions
Phase-1: Breath Holding Test, Phase 2: 6-Minute Walk Test (6MWT)
Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 19, 2026, 5:18 PM EDT
Terminated Phase 2 Interventional Results available

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

NCT01695330
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Subcutaneous bortezomib
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 19, 2026, 5:18 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 5:18 PM EDT
Completed Not applicable Interventional Results available

Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

NCT03212261
View directory record Official record
Conditions
Lymphoma
Interventions
3RP-Lymphoma
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 19, 2026, 5:18 PM EDT
Active, not recruiting Not applicable Interventional

AIR-B4: Remaking Recess (RR)

NCT04972838
View directory record Official record
Conditions
Autism Spectrum Disorder, Neurodevelopmental Disorders
Interventions
Remaking Recess (RR)
Behavioral
Lead sponsor
Health Resources and Services Administration (HRSA)
Federal
Eligibility
5 Years to 12 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Rochester, New York • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 19, 2026, 5:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine and Tobacco Message Framing to Change Smoking Behavior in Diverse Groups of Young Adult Smokers

NCT06644664
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Health Education, Interview, Smoking Cessation Intervention, Survey Administration, Text Message-Based Navigation Intervention
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 35 Years
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 19, 2026, 5:18 PM EDT
Recruiting Phase 1 Interventional

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

NCT06977711
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 5:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake

NCT01994018
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 19, 2026, 5:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrated BA and HIV RR Counseling for MSM With Stimulant Abuse

NCT03175159
View directory record Official record
Conditions
Stimulant Abuse, HIV Prevention, Substance Abuse
Interventions
IMPACT, Standard of Care
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 19, 2026, 5:18 PM EDT
Completed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

NCT02649790
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
Interventions
KPT-8602, ASTX727, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
26
States / cities
Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 19, 2026, 5:18 PM EDT